Dr Daver on the Investigation of Uproleselan Plus Azacitidine and Venetoclax in AML
September 22nd 2023Naval G. Daver, MD, discusses the rationale for an ongoing phase 1 trial investigating uproleselan in combination with azacitidine and venetoclax in patients with treatment-naïve acute myeloid leukemia.
Read More
Optimizing Treatment Selection for Patients with FLT3-ITD AML
Discussion centered around optimal strategies to effectively treat, and improve outcomes for, patients with FLT3-ITD AML.
Read More
Standard Approach to Treatment for Fit Patients with Newly Diagnosed AML
Recommendations for community oncologists concerning the treatment of fit patients diagnosed with AML.
Read More
Clinical Insights Concerning Molecular Testing in Patients Diagnosed with Acute Myeloid Leukemia
Eunice S. Wang, MD opens a discussion with other panelists concerning the benefits of germline testing in AML, NCCN guidelines for molecular testing, and how molecular testing in AML is advancing over time.
Read More
An Introduction to Biomarker Testing in Acute Myeloid Leukemia
Experienced clinicians highlight the role of biomarker testing in AML for optimal patient care and treatment selection.
Read More
An Overview of Incidence, Diagnosis, and Subtype Classification in Acute Myeloid Leukemia
Moderator Naval G. Daver, MD introduces expert panelists and leads an overview of Acute Myeloid Leukemia, focusing on the importance of timely diagnosis and risk assessment for patients with AML.
Read More
Dr. Daver Compares Toxicity Profiles of TKIs in CML
August 29th 2019Naval G. Daver, MD, associate professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses safety differences between the TKIs ponatinib, dasatinib (Sprycel) and nilotinib (Tasigna) in the treatment of patients with chronic myeloid leukemia.
Read More
Combination Checkpoint Therapy Gains Ground in AML and MDS
December 29th 2017Rational combinations of immune checkpoint inhibitors with other standard antileukemic agents may be needed to improve the response rates, the durability of response, and the overall survival in patients with AML/MDS.
Read More
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer
2 Commerce Drive
Cranbury, NJ 08512